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Abstract  
Rationale Ziprasidone is an atypical antipsychotic, with the unique multireceptor-binding 
profile. If affects multiple serotonergic (5-HT) receptors, inhibits 5-HT transporter (5-HTT) 
and inhibits synaptic 5-HT reuptake. These effects might be responsible for the antidepressant 
effect of ziprasidone. 
Objectives Since there is a lack of in vivo data on the effects of ziprasidone on 5-HT 
concentration in humans, the aim of the study was to investigate the effect of ziprasidone 
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treatment on platelet 5-HT concentration in patients with schizophrenia or schizoaffective 
disorders.  
Methods In and open-label study, the effect of ziprasidone (average dose of 109 mg/day) on 
platelet 5-HT concentration (determined fluorimetrically) was evaluated at baseline and after 
7 and 28 days of treatment in 21 male and female patients with schizophrenia or 
schizoaffective disorders.  
Results Ziprasidone treatment for 7 or 28 days did not significantly change baseline platelet 5-
HT concentration in male and female schizophrenic patients. Platelet 5-HT concentration was 
not correlated with gender, age and smoking status of patients.  
Conclusions There was a lack of effect of ziprasidone treatment on platelet 5-HT 
concentration in male and female schizophrenic patients. Although the clinical effects of 
ziprasidone were evident after 28 days of treatment, and ziprasidone has the highest potency 
among atypical antipsychotics to block 5-HTT, our data did not confirm the hypothesis that 
ziprasidone treatment decreases platelet 5-HT concentration, at least not in the doses used in 
our study. 
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Ziprasidone is an atypical antipsychotic, with higher ratio of 5-HT2A/D2, 5-HT2C/D2 and 5-
HT1A/D2 receptor binding than other antipsychotic drugs (Schmidt et al. 2001; Stahl and 
Shayegan 2007). It also blocks the serotonin transporter (5-HTT) and inhibits synaptic 5-HT 
reuptake (Tatsumi et al. 1999). Drugs that block the 5-HTT such as selective serotonin 
reuptake inhibitors (SSRI) have antidepressant properties, and ziprasidone is reported to have 
antidepressant effects in patients with depression (Moeller et al. 2007; Stahl and Shayegan 
2007). At present, however, it is unknown whether ziprasidone affects the 5-HTT in vivo 
when given to patients in therapeutic doses. Platelet 5-HT concentration is a reliable marker 
of the 5HTT blockade induced by SSRI, and reduced platelet 5-HT concentration is used as a 
marker of the biological activity of various SSRI (Muck-Seler et al. 2002). Therefore, the aim 
of the study was to investigate the effect of ziprasidone treatment on platelet 5-HT 
concentration in patients with schizophrenia or schizoaffective disorders. The hypothesis was 
that, if ziprasidone blocks 5-HTT, it will reduce platelet 5-HT concentration. 
An open-label, flexible-dose study included 21 (8 female and 13 male) patients with 
schizophrenia or schizoaffective disorder treated with ziprasidone (109.0 ± 27.1 mg/day, 
range 80-160), diagnosed using Structured Clinical Interview based on DSM-IV criteria, who 
were hospitalized due to inefficacy or adverse events of previous antipsychotic medication, or 
who stopped taking their antipsychotics prior to hospitalization. Exclusion criteria: treatment 
with ziprasidone, SSRI, tricyclic antidepressants or any other drug known to affect serotonin 
uptake in previous 4 weeks, past adverse reactions to ziprasidone, dementia, any other organic 
mental disorder, severe psychosis, severe depression, substance abuse and dependence in 
previous 3 months, abnormal ECG, the corrected (QTc) interval exceeding 450 ms. 
Benzodiazepines and hypnotics were allowed throughout the study. Anticholinergics were not 
routinely prescribed, but were allowed in the case of the emergence of extrapyramidal 
symptoms. Study was approved by the Ethics Committee of the University Hospital Centre 
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Zagreb, and has therefore been performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki. All subjects have signed written informed consent. 
Efficacy assessment was done using the Positive and Negative Syndrome Scale PANSS, 
Clinical Global Impression of Severity (CGI-S), and Calgary Depression Symptom scale 
(CDSS). Ratings were performed on baseline (within 24 hours before the first application of 
study drug), at the end of the 7 and 28 days of treatment. Three patients dropped out from the 
study and their basal samples were therefore excluded: 2 patients required SSRI treatment, 
and 1 patient withdrew consent. The following adverse events were reported during the study 
period: insomnia (N=2), headache (N=3), agitation (N=2), and muscular rigidity (N=1). Blood 
samples (8 ml) were collected into plastic syringes with 2 ml of acid citrate dextrose 
anticoagulant at 08.00 h. The determination of the platelet 5-HT concentration was done in 
platelet rich plasma using spectrofluorimetric method, as previously described (Muck-Seler et 
al. 1999). The results were expressed as means ± SD. Statistical evaluation of the data was 
done using one-way analysis of variance (ANOVA), followed by the Tukey’s multiple 
comparison test, and with multiple regression analysis. The level of significance was set at 
p=0.05.  
Platelet 5-HT concentration did not differ significantly [F(5, 57)= 0.298, p=0.912] between 8 
female and 13 male schizophrenic patients before, and after 7 and 28 days of ziprasidone 
treatment (Table 1). Multiple regression model was not significant (R
2
=0.183; adjusted R
2
=-
0.061; F(3,10)=0.749; p=0.547), and revealed that platelet 5-HT concentration was not 
significantly correlated to gender (t=0.441, Beta=0.130, p=0.669), age (t=-0.613, Beta=-
0.176, p=0.554), or smoking (t=1.293, Beta=0.385, p= 0.225). The treatment with ziprasidone 
significantly decreased total PANSS scores after 7 and 28 days of treatment [F(2, 62)= 8.771, 
p=0.001], and total CGI-S [F(2, 62)= 6.002, p=0.002], or CDS [F(2, 62)= 6.787, p=0.002] 
scores after 28 days of treatment with ziprasidone (data not shown).  
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To the best of our knowledge, no data on the effect of ziprasidone on platelet 5-HT 
concentration is yet available, and we have found the lack of effect of 7 and 28 days of 
treatment with ziprasidone (109 mg/day) on platelet 5-HT concentration in male of female 
schizophrenic patients. Ziprasidone treatment did not reduce platelet 5-HT concentration, and 
this finding might be explained by the suboptimal antidepressant dose of ziprasidone, 
although lower doses were also reported to be effective (Moeller et al. 2007), and the clinical 
effects of ziprasidone on symptoms of schizophrenia and depression were achieved with these 
lower doses (present study; Daniel el al. 1999). We could speculate that ziprasidone might 
have shown inhibitory effect on platelet 5-HT concentration if prescribed in higher doses 
(Daniel et al. 1999). Although ziprasidone has the highest potency for human 5-HTT (Kd=39 
nM) among atypical antipsychotics, its Kd is substantially weaker than that of SSRI 
paroxetine (Kd=0.13 nM), (Tatsumi et al. 1999), which was reported to reduce platelet 5-HT 
concentration after 28 days of treatment in depressed patients (Muck-Seler et al. 2002). The 
explanation of the antidepressant effect of ziprasidone might be due to other mechanisms, 
such as noradrenalin and dopamine reuptake blocking properties (Tatsumi se al. 1999), or 
5HT2A, 5HT2C and 5HT7 blocking properties (Schmidt et al. 2001; Stahl and Shayegan, 
2007). Although gender (Muck-Seler et al. 1999), smoking and age (Nenadic Sviglin et al. 
2011) significantly affected platelet 5-HT concentration in our previous studies, present study 
failed to detect significant effect of these variables on platelet 5-HT concentration. 
Limitations of the study are that patients receiving ziprasidone were not randomized, the 
number of included subjects was small, blood ziprasidone concentration was not measured 
and patient compliance was not checked. However, since all patients were hospitalized during 
the whole trial, ziprasidone intake was controlled by nurses.  
7 
 
In conclusion, ziprasidone did not significantly affect platelet 5-HT concentration in male and 
female schizophrenic patients. These findings strongly argue against our hypothesis that 
ziprasidone significantly affects 5-HT reuptake in vivo. 
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Table 1. Platelet 5-HT concentration in female and male schizophrenic patients before and 
after 7 and 28 days of treatment with ziprasidone. 5-HT= serotonin. Data are presented as 
means ± SD. Ziprasidone did not affect platelet 5-HT concentration  
 
 Platelet 5-HT (nmol/mg p) 
Schizophrenic patients At baseline After  7 days After  28 days 
Male 1.01 ± 0.34 1.05 ± 0.36 1.00 ± 0.19 
Female 1.04 ± 0.13 1.14 ± 0.43 0.98 ± 0.13 
 
